SHPGY Related Analyst Ratings
-
Barclays Upgrades Shire plc (SHPGY) to Overweight
-
Societe Generale Upgrades Shire plc (SHPGY) to Buy
-
Canaccord Genuity on Life Sciences: Generic Adderall XR Approval Offers Several Cross-stock Implications
-
Nomura Securities Maintains a 'Buy' on Shire plc (SHPGY); FDA Approved Generic Version of Adderall-XR
-
Actavis Adderall XR Approval Positive for Watson Pharm (WPI), Negative for Impax Lab (IPXL)
-
Leerink Swann Upgrades Shire plc (SHPGY) to Outperform; Market Opportunity Looks Compelling
-
Susquehanna Upgrades Shire plc (SHPGY) to Positive
-
Goldman Sachs Says Buy Shire plc (SHPGY) On Recent Weakness, Keeps Top Rating
-
Leerink Swann Starts Shire plc (SHPGY) at Market Perform; Growth Already Priced In; Wait for Better Entry
-
Deutsche Bank Maintains a 'Buy' on Shire plc (SHPGY) Despite Disappointing Lialda Diverticulitis Ph 3 Results
-
Baird Maintains an 'Outperform' on Shire plc (SHPGY); Like Clockwork, Another Positive Update & Outlook
-
Piper Jaffray Upgrades Shire plc (SHPGY) to Overweight
-
SocGen Upgrades Shire plc (SHPGY) to Buy
-
Barclays Downgrades Shire plc (SHPGY) to Equalweight
-
Shire plc (SHPGY) Shares on the Move Following Intraday Upgrade at UBS
-
William Blair Starts Shire plc (SHPGY) at Market Perform
-
BofA/Merrill Lynch Downgrades Shire plc (SHPGY) to Neutral
-
JPMorgan Downgrades Shire plc (SHPGY) to Neutral
-
Citadel Securities maintains an 'Add' on Shire (SHPGY); Strong HGT, Specialty Growth Continues; Raising PT
-
Citadel Securities Maintains an 'Add' on Shire plc (SHPGY); Replagal Lexington Approval a Good Step Forward
-
Citadel Securities maintains an 'Add' on Shire plc (SHPGY); Firazyr Approval Likely, but Market Opportunity Limited
-
Societe Generale Downgrades Shire plc (SHPGY) to Hold
-
Collins Stewart Downgrades Shire plc (SHPGY) to Sell
-
Citadel Securities Starts Shire plc (SHPGY) at Add, Sets $97 Price Target
-
JPMorgan Upgrades Shire plc (SHPGY) to Overweight
-
Jefferies Downgrades Shire plc (SHPGY) to Hold, Price Target $76
-
Susquehanna Starts Shire plc (SHPGY) at Neutral
-
Susquehanna Starts AGN, MRX, WCRX at Positive; FRX at Negative; CEPH, ENDP, KG, SHPGY at Neutral
-
Exane Downgrades Big Pharma Stocks AZN & SHPGY; Upgrades GSK
-
Goldman Sachs Upgraded Roche and Shire to Conviction Buy
-
Piper Jaffray Downgrades Shire plc (SHPGY) to Neutral
-
Citi Upgrades Shire plc (SHPGY) to Hold
-
Bernstein Downgrades Shire plc (SHPGY) to Market Perform
-
Piper Jaffray Specialty Pharma 2Q10 Preview: Street Estimates Sufficiently Conservative to Beatable
-
Credit Suisse Upgrades Shire Plc (SHPGY) to Outperform
-
Leerink Swann Says M&A Is One Reason To Get Involved In Biophama (AGN, DNDN, BMRN, HGSI, more...)
-
Lazard Capital Upgrades Shire Plc (SHPGY) to Buy
-
Deutsche Bank Maintains a 'Buy' on Shire PLC (SHPGY); HGT Business Continues to Gain Share; Raising PT & Estimates
-
J.P. Morgan Downgrades Shire plc (SHPGY) to Neutral
-
Citi Downgrades Shire (SHPGY) to Sell
-
Piper Jaffray Reiterates an 'Overweight' on Shire plc (SHPGY); Excellent 2010 Prospects and Beyond
-
Oppenheimer Upgrades Shire plc (SHPGY) to Outperform
-
Exane BNP Paribas Upgrades Biotechnology and Drugs Stocks SNY & SHPGY to Outperform
-
J.P. Morgan Upgrades Shire plc (SHPGY) to Overweight
-
Jefferies & Co Upgrades Shire plc (SHPGY) to Buy
-
RBS Starts Shire (SHPGY) at Sell
-
Jefferies Upgrades Shire plc (SHPGY) to Buy
-
Baird Maintains an 'Outperform' on Shire plc (SHPGY); Raises PT on Positive Outlook
-
UBS Downgrades Shire (SHPGY) to Neutral
-
Hapoalim Securities Initiates Coverage on Genzyme (GENZ) with a Hold; Pipeline Promising, But Near-Term Competition
Back to SHPGY Stock Lookup
